Sign In
Buy INSM
$103.86
+0.130 (+0.125%)
At Close: Jun 03, 2026
Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast
01:32pm, Wednesday, 11'th Jun 2025
Insmed Incorporated INSM on Tuesday released topline results from its Phase 2b study of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hy
Insmed Stock Jumps 29% on Encouraging PAH Study Results
12:06pm, Wednesday, 11'th Jun 2025
INSM eyes the next steps as TPIP hits all endpoints in the PAH study, setting the stage for late-stage trials and broader potential in lung disease.
Insmed CEO Will Lewis on stock surge after positive trial results
05:56pm, Tuesday, 10'th Jun 2025
Will Lewis, Insmed Chair & CEO, joins 'Fast Money' to talk its recent trial results for Pulmonary Arterial Hypertension therapy, the stock reaction, and more.
Insmed: Company Presses On With Further POC PAH Treatment Data
04:30pm, Tuesday, 10'th Jun 2025
Insmed achieved positive phase 2b results for TPIP in PAH, meeting all endpoints and paving the way for phase 3 trials in 2025-2026. The global pulmonary arterial hypertension market is expected to re
Liquidia price target lowered by $2 at BofA, here's why
01:19pm, Tuesday, 10'th Jun 2025
Liquidia -2.845 (-15.80%) Insmed +19.21 (+27.19%) 17 Jun
Insmed shares surge on positive trial results for pulmonary arterial hypertension therapy
11:04am, Tuesday, 10'th Jun 2025
Insmed Incorporated (NASDAQ:INSM) shares surged more than 27% after the company unveiled positive results from a Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil
Insmed's blood pressure drug meets main goal in mid-stage trial
07:25am, Tuesday, 10'th Jun 2025
Insmed said on Tuesday that its experimental blood pressure drug met the main goals in a mid-stage study.
–The Study Met Primary and All Secondary Efficacy Endpoints– Statistically Significant 35% Placebo-Adjusted Reduction from Baseline in Pulmonary Vascular Resistance for the Primary Endpoint (p
Mizuho's Jared Holz details potential biotech, pharma acquisitions
06:10pm, Wednesday, 04'th Jun 2025
Mizuho's Jared Holz joins the 'Fast Money' team to discuss the potential impact of expiring patents within the biotech and pharmaceuticals industries.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Wednesday, 04'th Jun 2025
BRIDGEWATER, N.J. , June 4, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference
07:10am, Wednesday, 28'th May 2025
BRIDGEWATER, N.J. , May 28, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study
04:05pm, Wednesday, 21'st May 2025
— Insmed Presented 11 Abstracts at ATS 2025 from Across Its Respiratory Portfolio, Including Data on ARIKAYCE® , TPIP and Health Economics and Outcomes Research — BRIDGEWATER, N.J. , May
Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects
10:21am, Tuesday, 13'th May 2025
Examine the evolution of Insmed's (INSM) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates
01:46pm, Friday, 09'th May 2025
INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.
Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript
02:55pm, Thursday, 08'th May 2025
Insmed Incorporated (NASDAQ:INSM ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Bryan Dunn - Investor Relations Will Lewis - Chair and Chief Executive Officer Sara Bons
